Complement C3 deficiency alleviates alkylation-induced retinal degeneration in mice
Eye and Vision volume 9, Article number: 22 (2022)
It has been found that the extensive use of anticancer drugs containing DNA-alkylating agents not only target cancer cells but also cause retinal inflammation through toxic intermediates. Complement C3 (C3) is a core component of the complement activation pathway, and dysregulation of the complement pathway is involved in several retinal degenerative diseases. However, whether C3 plays a critical role in alkylation-induced retinal degeneration is unclear.
Following treatment with the alkylating agent methyl methane sulfonate (MMS), the C3 mRNA and protein level was measured, DNA damage and photoreceptor cell death were assessed in both wild-type (WT) C57BL/6J and C3 knockout (KO) mice.
We determined that complement pathway is activated following MMS treatment, and C3 knockout (KO) increased the rate of photoreceptor cell survival and preserved visual function. The mRNA levels of nuclear erythroid-related factor 2 (Nrf2) and related genes were higher after MMS application in C3 KO mice.
In summary, our study found that C3 KO promotes photoreceptor cell survival and activates the Nrf2 signaling pathway in the context of alkylation-induced retinal degeneration.
Retinal degenerative diseases threaten people’s vision through the gradual degeneration of photoreceptor cells and supporting cells . Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are two major diseases involving the degeneration of photoreceptor cells. Currently, retinal degeneration is incurable and affects the lives of millions of individuals around the world . Aging, genetic mutations and smoking have been identified as risk factors for retinal degeneration . Alkylating agents, which are used as frontline chemotherapeutic drugs for cancer treatment, lead to extensive DNA damage in the body, which might cause retinal degeneration . However, the pathological mechanisms of retinal degeneration remain unclear . Therefore, it is important to elucidate the pathological mechanism underlying retinal degenerative diseases to aid the development of novel therapies.
It is well documented that oxidative stress induced by the environment and frontline chemotherapeutic drugs lead to DNA damage and apoptosis of photoreceptor cells . Antioxidants have been found to partially alleviate the progression of retinal degeneration in rd1 mice (an RP model) . A previous study also reported that retinal photoreceptor cells express P2X purinoceptor 7 (P2X7R) and that the P2X7 antagonist brilliant blue G (BBG), an approved adjuvant used in ocular surgery, prevents photoreceptor cell damage . It has also been proven that DNA damage repair is tightly linked to retinal degeneration . DNA damage can trigger the base excision repair (BER) pathway for alkylated DNA bases, and DNA damage is often repaired through BER; however, in some cells, BER intermediates can cause retinal cell damage . It has been demonstrated that treatment with the alkylating agent methyl nitrosourea (MNU) leads to visual function impairment in rodent models . In addition, Samson et al. reported that the application of methyl methane sulfonate (MMS) results in photoreceptor cell death in an animal model by activating the alkyladenine DNA glycosylase (AAG)-dependent signaling pathway . Some anticancer agents, such as bleomycin and temozolomide, are used to kill cancer cells but often induce DNA damage, leading to retinal degeneration [8, 11]. Recently, it was proven that inflammation is involved in alkylation-induced retinal degeneration . However, the exact downstream mechanism of alkylation-induced retinal degeneration needs further investigation.
The complement system plays an important role in retinal development and homeostasis . C3 is a core component of the complement activation pathway [13, 14], and C3 activation is essential for the initiation of retinal impairment [15, 16]. C3 plays a key role in retinal degeneration, including AMD . Upregulated expression and deposition of C3 have been observed in the degenerated retinas of both humans and animals [18,19,20,21]. Recent studies have found that inhibiting the complement activation pathway is a potential therapeutic strategy for AMD [22, 23]. However, whether C3 activation is involved in DNA-alkylating agent-induced retinal degeneration is unclear. Here, we found that activation of C3 caused extensive DNA damage and that MMS treatment led to photoreceptor cell apoptosis. Furthermore, knockout (KO) of C3 led to neuroprotection by increasing nuclear erythroid-related factor 2 (Nrf2) activity.
Eight-week-old C57BL/6J and C3 KO mice were used for this study. It was found that alkylation-induced retinal degeneration is sex dependent and that male animals are more sensitive to MMS [8, 24], so we chose to work with male mice for our study. C3 KO mice were kindly gifted by Professor Yusen Zhou (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China). All mice were housed in a temperature-controlled environment (21 °C ± 1 °C) on a normal 12-h light/dark cycle and provided ad libitum access to food and water. All animal protocols were conducted according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The animal protocol was approved by the Institutional Animal Care and Use Committee of the General Hospital of Chinese People’s Liberation Army and the Academy of Military Medical Sciences (ID number: 307-ky-090).
Treatment with MMS and tissue collection
MMS (Sigma, USA) was used to induce retinal degeneration. Male C57 and C3 KO mice were treated with a single i.p. injection of MMS at a sublethal dose of 75 mg/kg in saline . After electroretinography (ERG), eyeballs were collected and fixed using 4% paraformaldehyde.
Histology and immunofluorescence staining
After fixation for 24 h, the anterior segment of the eye was removed under a stereomicroscope, dehydrated by immersion in different concentrations of ethanol (70% ethanol for 20 min, 80% ethanol for 20 min, 90% ethanol for 20 min, 95% ethanol for 20 min, 100% ethanol for 20 min, and 100% ethanol for 20 min), cleared in xylene for 20 min twice and embedded in wax. Sections (5 μm) were prepared and used for hematoxylin and eosin (H&E) staining and immunofluorescent staining. The outer nuclear layer (ONL) thickness was evaluated throughout the whole retina . After dewaxing, sections were subjected to antigen retrieval as previously described . Primary antibodies were purchased from Abcam (anti-rhodopsin, ab221664, 1:600; anti-C3, ab225539, 1:600; mouse monoclonal anti-DNA/RNA Damage [15A3], ab62623, 1:600). All sections were stained under the same conditions. Negative control slides (no primary antibody) were used to set the confocal laser power and collection parameters. The same confocal parameters were used for all slides, and images of the retina at the same site were captured with a laser confocal microscope for all mice in each experiment. The fluorescence intensity in each image was measured with ImageJ . Statistical analyses were performed using SPSS.
Animals underwent ERG before and 1, 3, and 7 days after MMS injection as previously described . Briefly, mice were dark-adapted for 12 h. Under dim red light conditions, the pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine eye drop solution (Santen Pharmaceutical Co., Ltd., Osaka, Japan). The mice were anesthetized with isoflurane and kept warm to prevent hypothermia. A flashlight intensity of 0.5 log (cd s/m2) was used for all experiments. The ERG response was recorded with a corneal active gold electrode. The amplitudes of both the a and b waves were assayed.
TdT-UTP nick end labeling (TUNEL) staining was performed according to the manufacturer’s instructions (Beyond, Shanghai). The slices were incubated with protease K (2 μg/mL) for 15 min at room temperature and washed three times with phosphate buffered saline (PBS) for 5 min each. Then, TUNEL solution was added for 30 min at 37 °C. After washing three times with PBS, DAPI was applied to counterstain the nuclei. Images were captured with a laser confocal microscope. ImageJ was used to process the images and semi-quantify the fluorescence intensity.
Real-time qPCR (RT-qPCR)
The eyeballs were washed with clean cold PBS and then dissected on ice. The neural retina, retinal pigment epithelium (RPE) and choroidal tissue were quickly collected. mRNA was extracted with TRIzol (Thermo Fisher, USA), and cDNA was synthesized using iScript cDNA Synthesis kits (Bio-Rad, USA). RT-qPCR was performed as previously described . Real-time PCR was performed using SYBR Green master mix (Bio-Rad, USA) on a CFX96 Bio-Rad system (Bio-Rad, USA) following the manufacturer’s instructions. The following PCR cycle parameters were used: 95 °C for 10 s and 40 cycles of 95 °C for 5 s and 60 °C for 34 s. Each reaction was performed in triplicates, and mβ-Actin1 was used as a reference gene. The primers used in this study are listed in Table 1.
Statistical analysis was performed using SPSS 19.0 (Armonk, NY, USA). Two-tailed unpaired Student’s t test were used for statistical analysis. All quantitative values are presented as the mean ± standard error of the mean (SEM). Differences were considered significant at P < 0.05.
The complement pathway is activated in the MMS-induced retinal degeneration model
Previous studies have shown a strong connection between C3 and retinal degeneration . However, the function of C3 in DNA-alkylating agent-induced retinal disease is unclear. MMS was administered to induce retinal injury . Meira et al. observed profound loss of the photoreceptor layer after exposure to a medium dose of MMS (75 mg/kg) for 1 week. Therefore, we used 75 mg/kg MMS here. C3 protein was detected in retinal neural layers and the choroid layer (Fig. 1a). Semi-quantification of C3 expression revealed sharp upregulation of C3 expression 1 day after MMS injection. The expression level gradually decreased during degeneration but was still significantly higher in the MMS group than in the control group (Fig. 1a, b; P < 0.001, n = 6). We observed that the mRNA level of C3 was significantly higher in the MMS group than in the control group at 1, 3, and 7 days (Fig. 1c; P < 0.001, n = 6). These data indicated that upregulated expression of C3 may be correlated with the development of MMS-induced retinal degeneration.
C3 deficiency preserves retinal function
Since we found an increase in the production of C3 in the MMS-treated mouse retina, we aimed to elucidate the function of C3 using the MMS-induced retinal degeneration model. We administered MMS (75 mg/kg) to wild-type (WT) and C3 KO mice and observed them for 1 week. MMS treatment led to an extinguished electroretinogram, with a sharp decline in the a- and b-wave amplitudes, in WT mice (Fig. 2a; P < 0.001, n = 6). On the other hand, we observed that retinal function was partially preserved in C3 KO mice, with a and b wave amplitudes being higher than those in littermate WT animals (Fig. 2b, c; P < 0.001, n = 6). This result suggested that genetic deletion of C3 had a remarkable effect on mitigating the damaging effect of MMS on retinal function.
C3 deficiency protects against photoreceptor cell injury
Consistent with the data presented above, H&E staining of the retina showed disorganization of the photoreceptor layer from 1 day after MMS injection. Degeneration of photoreceptor cells was observed, and the thickness of the ONL was decreased in WT mice (Fig. 3a); however, photoreceptor cell degeneration was partially rescued in the C3 KO group from 1 to 7 days after MMS injection (Fig. 3a, b). These results suggested that activation of C3 in WT mice induced photoreceptor cell injury (P < 0.001, n = 6). Additionally, RT-qPCR and immunofluorescence staining showed that rhodopsin mRNA and protein levels were dramatically decreased in WT mice, while the degree to which rhodopsin mRNA and protein levels were decreased was significantly alleviated in C3 KO mice (Fig. 4a–c; P < 0.001, n = 6). In summary, these data indicate that loss of C3 dramatically reduces MMS-induced photoreceptor cell loss.
C3 deficiency rescues photoreceptor cell apoptosis
TUNEL staining was used to determine whether loss of C3 could rescue photoreceptor cell death. There were no TUNEL-positive cells before MMS treatment in either WT or C3 KO mice (Fig. 5a). As shown in the curve of the semi-quantification data, TUNEL-positive cells appeared in the ONL 1 day after MMS injection and the number of these cells reached a peak at 3 days and then gradually decreased in the WT group (Fig. 5b). The ratio of TUNEL-positive cells decreased in 3-day-old MMS-treated C3 KO mice compared with 3-day-old MMS-treated WT mice (Fig. 5a, b; P < 0.001, n = 6). Taken together, these showed that loss of C3 could effectively rescue photoreceptor cell apoptosis.
C3 deficiency reduces retinal DNA damage
To quantify and better characterize the mechanism of alkylation-induced retinal cell injury, the level of DNA damage was analyzed by immunofluorescence staining using an anti-DNA damage antibody. We detected extensive DNA damage in the positive group of NaIO3-induced oxidative stress retinal injury model (Additional file 1: Fig. S1). Extensive DNA damage was observed soon after MMS treatment in the WT group on 1 day, while the damage was limited to the ONL in C3 KO mice (Fig. 6a). Similar results were observed in 3- and 7-day samples (Fig. 6a). Moreover, the curve of the semi-quantified data showed that the ratio of DNA damage-positive cells decreased in the C3 KO group compared with the WT group (Fig. 6b; P < 0.001, n = 6). This result indicated that C3 deficiency reduced DNA damage not only in photoreceptor cells but also in whole retinal cells.
C3 deficiency exhibits a Nrf2-mediated protective effect
Furthermore, we determined whether C3 deficiency alleviates oxidative stress levels by measuring the mRNA levels of Nrf2, Nqo1, Hmox-1 and Sod2 before and 1, 3, and 7 days after MMS treatment. The mRNA levels of Hmox-1 and Nqo1 were upregulated in C3 KO mice compared with WT control mice. Nrf2, Nqo1, Hmox-1 and Sod2 mRNA levels were decreased in WT mice 1 day after MMS treatment (Fig. 7; P < 0.001, n = 6). The mRNA levels of these oxidative stress genes were upregulated in C3 KO mice compared to WT mice 1, 3, and 7 days after MMS treatment (Fig. 7; P < 0.001, n = 6). Taken together, these demonstrate that antioxidation was increased in C3 KO mice following MMS treatment and that C3 deficiency exerted neuroprotection via the Nrf2 signaling pathway.
C3 is a core immune system component that is essential for maintaining neural system homeostasis . The function of C3 in alkylating agent-induced retinal degeneration in mice was studied in our experiments. C3 deficiency partially rescued photoreceptor cell apoptosis and preserved visual function by promoting the antioxidative signaling pathway and effectively attenuated a DNA alkylating agent-induced retinal degeneration.
Previous studies have found that AAG, a DNA repair protein, activates the BER pathway, which plays an important role in alkylation-induced retinal degeneration in animals . AAG is an enzyme that can cleave the glycosyl bond connecting the base to the sugar phosphate backbone and then remove alkylated bases. This process generates a basic site that can be further processed by the BER machinery. Further research has revealed that the AAG-initiated base excision response is PARP1 dependent . However, it is unclear whether inflammation is involved in alkylation-induced retinal degeneration. Allocca et al., however, demonstrated that inflammation played a crucial role in alkylation-induced retinal degeneration .
Further, we demonstrated that C3 activation contributes to photoreceptor cell apoptosis during alkylating agent-induced oxidative stress. This result is consistent with a previous report showing that inactivation of C3 alleviates retinal injury [31, 32]. In our experiments, we observed extensive DNA damage in retinal cells in wild-type animals, but only photoreceptor cells went through apoptosis. It seems that photoreceptor cells are more sensitive than other retinal cells to MMS. MMS treatment caused extensive DNA damage in retinal cells in wild-type mice. However, the damage to photoreceptor cells was limited in C3 KO mice. This was likely due to the protective effect of C3 deficiency. Moreover, we observed that C3 deficiency resulted in neuroprotection via Nrf2 activation. Activation of Nrf2 and downstream antioxidant-responsive elements (AREs) can protect neurons from damage and alleviate CNS disorders .
Nrf2 is an endogenous oxidative stress sensor. Under oxidative stimulation, Nrf2 can dissociate from Kelch-like ECH-associated protein 1 (Keap1) and activate the transcription of Sod2, Ho-1 and Nqo-1. Keap1 and Nrf2 play a central role in monitoring endogenous antioxidant enzyme activity. Here, MMS treatment significantly downregulated the expression of Nrf2, antioxidant enzymes, HO-1 and Nqo1. C3 deficiency partially reversed the downregulation of the expression of these genes. These results indicated that C3 could regulate the Nrf2-ARE pathway during retinal degeneration. However, C3 KO could not totally prevent retinal degeneration. Other inflammatory reactions might also be involved in alkylation-induced retinal degeneration. Additional work is therefore needed to elucidate the detailed mechanism underlying the effect of C3 on the Nrf2 signaling pathway.
In summary, our study found that alkylating agent MMS treatment induced photoreceptor cell degeneration and activation of complement pathway. Moreover, C3 KO promotes photoreceptor cell survival and activates the Nrf2 signaling pathway in the context of alkylation-induced retinal degeneration. Our data suggests that inhibition of complement pathway might be helpful for treatment of alkylating agent induced retinal degeneration.
Availability of data and materials
Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, et al. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019;10(1):3347.
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.
Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107(12):2224–32.
Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12(2):104–20.
Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489-551.
Komeima K, Rogers BS, Lu L, Campochiaro PA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci USA. 2006;103(30):11300–5.
Spadaro A, Rao M, Lorenti M, Romano MR, Augello A, Eandi CM, et al. New Brilliant Blue G derivative as pharmacological tool in retinal surgery. Front Pharmacol. 2020;11:708.
Allocca M, Corrigan JJ, Mazumder A, Fake KR, Samson LD. Inflammation, necrosis, and the kinase RIP3 are key mediators of AAG-dependent alkylation-induced retinal degeneration. Sci Signal. 2019;12(568):eaau9216.
Nakajima M, Yuge K, Senzaki H, Shikata N, Miki H, Uyama M, et al. Photoreceptor apoptosis induced by a single systemic administration of N-methyl-N-nitrosourea in the rat retina. Am J Pathol. 1996;148(2):631–41.
Meira LB, Moroski-Erkul CA, Green SL, Calvo JA, Bronson RT, Shah D, et al. Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. Proc Natl Acad Sci USA. 2009;106(3):888–93.
Rai G, Vyjayanti VN, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM, et al. Small molecule inhibitors of the human apurinic/apyrimidinic endonuclease 1 (APE1). In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97.
Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3—The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev. 2016;274(1):33–58.
Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement dysregulation and disease: insights from contemporary genetics. Annu Rev Pathol. 2017;12:25–52.
van Lookeren CM, Strauss EC, Yaspan BL. Age-related macular degeneration: complement in action. Immunobiology. 2016;221(6):733–9.
Mohlin C, Sandholm K, Ekdahl KN, Nilsson B. The link between morphology and complement in ocular disease. Mol Immunol. 2017;89:84–99.
Kim BJ, Mastellos DC, Li Y, Dunaief JL, Lambris JD. Targeting complement components C3 and C5 for the retina: key concepts and lingering questions. Prog Retin Eye Res. 2021;83:100936.
Linetsky M, Bondelid KS, Losovskiy S, Gabyak V, Rullo MJ, Stiadle TI, et al. 4-hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of the complement pathway in human retinal pigmented epithelial cells. Chem Res Toxicol. 2018;31(8):666–79.
Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.
Chi ZL, Yoshida T, Lambris JD, Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol. 2010;703:127–35.
Ramos de Carvalho JE, Klaassen I, Vogels IM, Schipper-Krom S, van Noorden CJ, Reits E, et al. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration. Invest Ophthalmol Vis Sci. 2013;54(10):6489–501.
Park DH, Connor KM, Lambris JD. The challenges and promise of complement therapeutics for ocular diseases. Front Immunol. 2019;10:1007.
Di Carlo E, Augustin AJ. Prevention of the onset of age-related macular degeneration. J Clin Med. 2021;10(15):3297.
Allocca M, Corrigan JJ, Fake KR, Calvo JA, Samson LD. PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration. Oncotarget. 2017;8(40):68707–20.
Wang J, Iacovelli J, Spencer C, Saint-Geniez M. Direct effect of sodium iodate on neurosensory retina. Invest Ophthalmol Vis Sci. 2014;55(3):1941–53.
Wang S, Poli S, Liang X, Peng GH. Longitudinal single-cell RNA-seq of hESCs-derived retinal organoids. Sci China Life Sci. 2021;64(10):1661–76.
Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: an open platform for biomedical image analysis. Mol Reprod Dev. 2015;82(7–8):518–29.
Zou T, Gao L, Zeng Y, Li Q, Li Y, Chen S, et al. Organoid-derived C-Kit(+)/SSEA4(−) human retinal progenitor cells promote a protective retinal microenvironment during transplantation in rodents. Nat Commun. 2019;10(1):1205.
Wang S, Du L, Peng GH. Optogenetic stimulation inhibits the self-renewal of mouse embryonic stem cells. Cell Biosci. 2019;9:73.
Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017;9(392):eaaf6295.
Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravante N, Rothman AM, et al. Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain. 2019;142(9):2722–36.
Natoli R, Fernando N, Jiao H, Racic T, Madigan M, Barnett NL, et al. Retinal macrophages synthesize C3 and activate complement in AMD and in models of focal retinal degeneration. Invest Ophthalmol Vis Sci. 2017;58(7):2977–90.
Wang Z, Chen Z, Jiang Z, Luo P, Liu L, Huang Y, et al. Cordycepin prevents radiation ulcer by inhibiting cell senescence via NRF2 and AMPK in rodents. Nat Commun. 2019;10(1):2538.
This work was supported by grants from the National Key Research and Development Program of China (2018YFA0107303) and the National Natural Science Foundation of China (82070990).
Ethics approval and consent to participate
All animal protocols were conducted according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The animal protocol was approved by the Institutional Animal Care and Use Committee of the General Hospital of Chinese People’s Liberation Army and the Academy of Military Medical Sciences (ID number: 307-ky-090). C57BL/6J mice were provided by Charles River Laboratories (Beijing, China). C3 KO mice were kindly gifted by Professor Yusen Zhou (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China).
Consent for publication
The authors declare that they have no competing interests.
DNA damage in sodium iodate (NaIO3)-treated mouse retinas. a. Representative images of DNA damage staining in retinal cross sections from each group before and 7 days after NaIO3 injection. b. Semi-quantification of DNA damage using ImageJ. There are DNA damage-positive cells in the retina after NaIO3 injection (n = 6, ***P < 0.001 compared with control).
About this article
Cite this article
Du, L., Peng, GH. Complement C3 deficiency alleviates alkylation-induced retinal degeneration in mice. Eye and Vis 9, 22 (2022). https://doi.org/10.1186/s40662-022-00292-4